Search

everythinglearnresearchcommunity

for

Search:↓

The user experienced significant hair regrowth using 1mg finasteride daily and Bosley minoxidil foam once a week, along with a derma roller and Hims shampoo and conditioner. They noted a decrease in sex drive as a side effect of finasteride.

A new hair loss treatment, PP405, is moving from phase 2A to 2B in clinical trials, sparking discussions about its potential to regrow dormant hairs and its impact on existing treatments like Minoxidil and finasteride. Some users express skepticism, while others are hopeful about its future effectiveness.

New product Tomorrowlabs HSF targets hair loss through HIF pathway indirectly by removing scalp iron. Minoxidil and Stemoxydine also relate to HIF pathway.

A 22-year-old male has been using finasteride for 4 months without major side effects but is concerned about hormone test results showing low SHBG and high estrogen. He plans to consult a doctor and is considering alternatives like minoxidil or topical finasteride to avoid health issues.

The user is asking for opinions on whether their hair growth is due to Pantostin and hormone treatments. One commenter confirms regrowth and asks about the hormone treatments.

The user noticed increased hair fullness after using a minoxidil and finasteride oral capsule but is unsure if the 1.25 mg minoxidil dose is sufficient. They are considering switching to a higher dose and are waiting for a dermatologist's advice.

GT20029 and PP405 are discussed as potential alternatives or complements to finasteride for hair loss treatment. GT20029 is entering phase 3 trials, while PP405 is seen as promising for regrowing hair and possibly eliminating the need for other treatments.

A user's successful 4-month hair growth progress using Hims spray with 6% Minoxidil, 0.3% Finasteride, and a .25mm dermaroller twice a week. The user applies the spray once a day and has not experienced any side effects.

PP405 may promote short-term hair growth by pushing follicles into the growth phase, but concerns exist about long-term effects due to lack of rest phases. Users discuss various treatments like finasteride, minoxidil, spironolactone, alfatradiol, and investigational drugs like KX-826 and GT20029 for hair maintenance and regrowth.

PP405 is in phase 2 trials for hair loss, with discussions on its cost and effectiveness compared to minoxidil and finasteride. Users are skeptical about its efficacy and timeline, with hopes for market release by 2027.

The conversation is about the use of peptide therapies for hair loss, specifically GHK-CU, ZN-Thymulin, and PTD-DBM. The user is seeking feedback on the effectiveness of these treatments from those who have tried them.

The conversation is about the results of using hormone replacement therapy (HRT) with estrogen and finasteride for hair loss, and switching from finasteride to bicalutamide as an anti-androgen treatment. The user shared before and after photos to discuss the effectiveness of these treatments.

The user has been using Hims finasteride and minoxidil spray, nizoral shampoo twice a week, and a daily biotin gummy for 90 days to treat hair loss. The user and others discuss the cost, dosage, and effectiveness of the treatment, with some suggesting cutting hair short for better results.

New hair loss treatments include topical and gel formulations combining finasteride and dutasteride, with added caffeine and melatonin. The user reports positive results from using topical dutasteride.

AHK-Cu peptide is considered better than GHK-Cu for hair growth. The user is seeking recommendations for trusted AHK-Cu peptide brands with third-party testing.

User's hair loss journey includes Minoxidil 5%, HIM's topical finasteride and minoxidil, derma rolling, and rosemary oil. Experiences some side effects, still considering hair transplant for better hairline.

AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.

A user has been taking finasteride for 5 months with no improvement in diffuse hair loss and suspects high levels of prolactin, cortisol, progesterone, and DHEAS, as well as iron, might be contributing to the issue. They are also taking vitamin D to address a deficiency.

PP405 shows promise for hair follicle reactivation with minimal side effects. Users recommend continuing Minoxidil and Finasteride until more results are confirmed.

GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.

A user shared progress pictures after 5 months using Hims 2-in-1 finasteride and minoxidil with a 1.5mm derma roller. Other users commented positively and shared their own experiences with the treatment.

The conversation discusses the potential of PP405 as a hair loss treatment, with some users expressing skepticism and others hopeful about its development. There is also mention of other treatments like Minoxidil, Finasteride, and Pyrilutamide, with users debating the effectiveness and safety of self-experimentation versus waiting for clinical trial results.

A 30-year-old male shares his 6-month progress using 1mg oral finasteride and 2.5mg oral minoxidil, noting increased hair thickness and regrowth. He also mentions using supplements like biotin and cod liver oil and discusses the convenience of combined pills.

A clinical trial for hair loss treatments involving Minoxidil, Finasteride, and RU58841, and when the results of the trial will be available.

PP405 is a potential hair loss treatment, but its safety and effectiveness are uncertain. Users advise caution and suggest waiting for more data before purchasing unverified versions.

PP405 is a new hair loss treatment targeting dormant hair follicles, with ongoing trials. Some users consider stopping finasteride and minoxidil to join trials, while others doubt its effectiveness.

P-1075 is a more potent hair growth agent than Minoxidil, but it poses significant heart risks, making it unsafe for use. Despite promising results in macaques, concerns about its cardiotoxicity in rats have halted its development.

PP405 is discussed as a potential hair loss treatment, but its effectiveness and safety are uncertain. Some users express skepticism, while others are hopeful, comparing it to existing treatments like Minoxidil and Finasteride.

The user is using testosterone and finasteride to prevent hair loss and is considering adding Primobolan or Masteron, which are DHT-derivatives. They are seeking advice on their genetic risk for male pattern baldness and whether they can safely use these compounds without significant hair loss.

PP405 is seen as promising but uncertain, with users advised to continue using existing treatments like minoxidil and finasteride. Concerns include its cost, availability, and interaction with hair transplants, while some hope it could complement current treatments.